#USA #San Diego #biopharmaceuticals #Neurocrine Biosciences #Andrew Ratz

Neurocrine Biosciences Promotes Andrew Ratz, Ph.D. to Chief Technical Operations Officer

SAN DIEGO, March 17, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced the promotion of Andrew Ratz, Ph.D., to the vital role of Chief Technical Operations Officer (CTO). This strategic move comes as Neurocrine seeks to strengthen its global technical development, manufacturing, and supply chain functions, particularly as it expands into biologics and device-based therapies.

A Visionary Leader

Dr. Ratz's journey with Neurocrine began in January 2025 when he joined as Senior Vice President of Drug Development, Delivery, and Device. His extensive experience of nearly three decades includes a significant tenure at Eli Lilly and Company, where he was responsible for a vast array of drug and device development projects. Dr. Ratz played an instrumental role in the successful registration and development of over 25 medicines across various therapeutic areas, cleverly balancing the needs of both biologics and small molecule portfolios.

Kyle W. Gano, Ph.D., the Chief Executive Officer of Neurocrine Biosciences, praises Dr. Ratz for his visionary leadership and strategic focus, stating, “Since joining Neurocrine, Andy has brought visionary leadership to our R&D organization. His skills and experience are pivotal as we advance the next generation of treatments for patients with significant unmet needs.”

Commitment to Patient-Centric Innovation

In his new role as CTO, Dr. Ratz is excited to help lead efforts that turn scientific innovation into meaningful patient benefits. He expresses his aspirations, stating, “My career has been shaped by a focus on turning scientific innovation into real benefits for patients. As a member of Neurocrine's leadership team, I look forward to helping build momentum around our efforts to develop therapies that can meaningfully improve patients' lives.”

Academic Foundation

Dr. Ratz’s academic background is impressive. He holds a Bachelor of Science degree in Chemistry from Indiana University and has earned a Ph.D. in Chemistry from Harvard University. This solid foundation in scientific research and innovation positions him well for his new responsibilities at Neurocrine.

Neurocrine Biosciences: A Legacy of Transformation

Neurocrine Biosciences is a leader in the biopharmaceutical field, centered on relieving the suffering of individuals facing complex health conditions. The company is committed to discovering and developing transformative treatments focused on neurological, psychiatric, endocrine, and immunological disorders.

Their robust portfolio boasts FDA-approved therapies for conditions such as tardive dyskinesia and endometriosis. An innovative approach and a diversified pipeline, which includes several compounds in mid- to late-phase clinical development, position Neurocrine as a critical player in the biopharmaceutical landscape.

For several decades, the company has leveraged unique insights into neuroscience to tackle intricate health problems, continually driven by their commitment to creating life-altering medications.

Looking Ahead

With Dr. Ratz now at the helm of technical operations, Neurocrine Biosciences is poised to accelerate its growth and meet the evolving needs of patients who have previously been underserved. As they pursue innovative treatment solutions, their mission remains clear: To ease the burden of debilitating diseases through brave, pioneering science.

For further information, visit their official website at neurocrine.com or follow them on LinkedIn, X, Facebook, and YouTube.